Lesson plan
EXS4318
EXS4318 is a selective PKC theta inhibitor that is potentially first-in-class medication. Developed by Exscientia, it was licensed to Bristol Myers Squibb. In 2023, it entered clinical trials in humans.
Article summary
EXS4318 is a selective PKC theta inhibitor that is potentially first-in-class medication. Developed by Exscientia, it was licensed to Bristol Myers Squibb. In 2023, it entered clinical trials in humans.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.